Administration of Antibiotics and Therapeutic Agents

• US 20150258320A1
• Filed: 05/29/2015
• Published: 09/17/2015
• Est. Priority Date: 09/12/2008
• Status: Active Grant

• Current Assignee: Sonescence, Inc.
• Original Assignee: Sonescence, Inc.
• Inventors: Silberg, Barry Neil
• Granted Patent: US 10,099,045 B2
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A61B 17/3211 Surgical scalpels, knives; Accessories therefor
• CPC Class Codes: A61B 2017/00889 antimicrobial, disinfectant
• CPC Class Codes: A61K 31/546 containing further heterocyclic rings, e.g. cephalothin
• CPC Class Codes: A61K 38/14 Peptides containing saccharide radicals; Derivatives thereof , e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
• CPC Class Codes: A61M 37/0092 using ultrasonic, sonic or infrasonic vibrations, e.g. phonophoresis
• CPC Class Codes: A61N 2007/0004 Applications of ultrasound therapy
• CPC Class Codes: A61N 2007/0017 Wound healing
• CPC Class Codes: A61N 7/00 Ultrasound therapy lithotripsy A61B17/22, A61B17/225; massage using supersonic vibration A61H23/00 ; using ultrasound for introducing media into the body A61M37/0092

Abstract

Antibiotics are administered in a surgical site subcutaneously via a small or stab incision in the surgical field. Transcutaneous ultrasonic vibrations are applied across the surgical field, which is then opened in the usual manner, to thereby provide a surgical field which contains a vastly higher and more effective level of antibiotic. At the same time the underlying tissue is hydrated.

Claims

1. A MRSA infection treatment system for treating MRSA infected tissue of a patient, the MRSA infection treatment system comprising:

an ultrasound system configured to broadcast ultrasound transcutaneously toward a treatment field associated with the MRSA infected tissue that has been injected subcutaneously with a solution, wherein the ultrasound system is configured to broadcast ultrasound that interacts with the subcutaneously injected solution to disperse the subcutaneously injected solution with a therapeutic dose of Cefazolin dissolved therein through the treatment field and into the MRSA infected tissue via microstreaming or by cavitation; and

wherein the broadcasted ultrasound is configured to interact with the subcutaneously injected solution to disperse the therapeutic dose of Cefazolin through the MRSA infected tissue at therapeutically effective concentrations for treating the MRSA infected tissue; and

wherein the Cefazolin is not in encapsulated in vesicles.

2. The MRSA infection treatment system of claim 1, wherein a minimum inhibitory concentration of the Cefazolin with respect to the MRSA infection is at least 64 micro grams/ml.

3. The MRSA infection treatment system of claim 2, wherein the minimum inhibitory concentration of the Cefazolin with respect to the MRSA infection is at least 128 micrograms/ml.

4. The MRSA infection treatment system of claim 3, wherein the minimum inhibitory concentration of the Cefazolin with respect to the MRSA infection is at least 512 micrograms/ml.

5. A MRSA infection treatment system for treating MRSA infected tissue of a patient, the MRSA infection treatment system comprising:

an ultrasound system configured to broadcast ultrasound transcutaneously toward a treatment field associated with the MRSA infected tissue and a subcutaneously injected 250 cc of solution, wherein the ultrasound system is configured to broadcast ultrasound that interacts with the 250 cc of solution to disperse the 250 cc of solution with a therapeutic dose of Cefazolin or Vancomycin dissolved therein through the treatment field and into the MRSA infected tissue via microstreaming or by cavitation; and

wherein the broadcasted ultrasound is configured to interact with the 250 cc of solution to disperse the therapeutic dose of Cefazolin or Vancomycin through the MRSA infected tissue at therapeutically effective concentrations for treating the MRSA infected tissue.

6. The MRSA infection treatment system of claim 5, further comprising the 250 cc of solution with the therapeutic dose of Cefazolin or Vancomycin dissolved therein for subcutaneous injection into the treatment field associated with the MRSA infected tissue.

7. The MRSA infection treatment system of claim 6, further comprising an infusion needle having a blunt tip for delivery of the 250 cc of solution with the therapeutic dose of Cefazolin or Vancomycin dissolved therein into the treatment field associated with the MRSA infected tissue.

8. The MRSA infection treatment system of claim 6, further comprising a solution warmer for prewarming the 250 cc of solution prior to subcutaneous injection.

9. The MRSA infection treatment system of claim 5, wherein the broadcasted ultrasound is configured to interact with the 250 cc of solution to disperse the 250 cc of solution with the therapeutic dose of Cefazolin or Vancomycin dissolved therein down to a deep fascia tissue of the patient.

10. The MRSA infection treatment system of claim 5, wherein the ultrasound system is configured to broadcast ultrasound transcutaneously toward the treatment field associated with the MRSA infected tissue and the subcutaneously injected 250 cc of solution for less than 5 minutes.

11. The MRSA infection treatment system of claim 5, further comprising a temperature monitor for monitoring a temperature of the treatment field during treatment of the MRSA infected tissue.

12. The MRSA infection treatment system of claim 5, wherein the ultrasound system is configured to broadcast ultrasound at a power density of 2.5 to 4 W/cm2 and at a frequency less than 5 MHz for less than 5 minutes.

13. The MRSA infection treatment system of claim 5, wherein the 250 cc of solution includes a therapeutic dose of Cefazolin dissolved therein, wherein the therapeutic concentration of Cefazolin dissolved in the at least 250 cc of solution is dispersed through the infected tissue at a concentration of at least 800 micrograms/ml after the application of transcutaneous ultrasound while maintaining a serum concentration of less than 10 micrograms/ml one hour after the application of transcutaneous ultrasound.

15. The MRSA infection treatment system of claim 5, wherein the 250 cc of solution includes a therapeutic dose of Vancomycin dissolved therein, wherein the therapeutic dose of Vancomycin dissolved in the at least 250 cc of solution is less than a therapeutic dose of Vancomycin required for intravenous injection or for oral administration.

14. The MRSA infection treatment system of claim 14, wherein the therapeutic concentration of Cefazolin dissolved in the at least 250 cc of solution is dispersed throughout the infected tissue at a concentration of at least 200 micrograms/ml fifty minutes after the application of transcutaneous ultrasound, wherein the concentration of Cefazolin in the infected tissue is therapeutically effective against the MRSA infection while the maintaining of the serum concentration to less than 10 micrograms/ml one hour after the application of transcutaneous ultrasound, wherein maintaining the serum concentration to less than 10 micrograms/ml one hour after the application of transcutaneous ultrasound reduces adverse side effects to bacterial flora in a gastrointestinal tract of the patient.

16. A MRSA infection treatment system for treating MRSA infected tissue of a patient with a reduced dose of antibiotic that is less than an intravenous dose associated with the antibiotic, the MRSA infection treatment system comprising:

250 cc of a solution with the reduced therapeutic dose of the antibiotic dissolved therein for subcutaneous injection into a treatment field associated with the MRSA infected tissue, the reduced therapeutic dose of the antibiotic being less than the intravenous therapeutic dose of the antibiotic;

an ultrasound system configured to broadcast ultrasound transcutaneously toward the treatment field associated with the MRSA infected tissue and the subcutaneously injected 250 cc of solution, wherein the ultrasound system is configured to broadcast ultrasound that interacts with the 250 cc of solution to disperse the 250 cc of solution with the reduced therapeutic dose of antibiotic dissolved therein through the treatment field and into the MRSA infected tissue; and

wherein the broadcasted ultrasound is configured to interact with the 250 cc of solution to disperse the reduced therapeutic dose of antibiotic through the MRSA infected tissue at therapeutically effective concentrations for treating the MRSA infected tissue, thereby reducing side effects associated with the intravenous dose of the antibiotic.

17. The MRSA infection treatment system of claim 17, wherein the antibiotic is a beta-lactam or Vancomycin.

19. The MRSA infection treatment system of claim 17, wherein a minimum inhibitory concentration of the antibiotic with respect to the MRSA infection is at least 64 micrograms/ml.

20. The MRSA infection treatment system of claim 17, wherein a minimum inhibitory concentration of the antibiotic with respect to the MRSA infection is more than ten times an antibiotic concentration achievable by intravenous administration.

18. The MRSA infection treatment system of claim 18, wherein the intravenous dose is 1 g or greater and the reduced dose is less than 1 g.